Gene · 369
Papers2,279
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 2,279
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment. | Dis Model Mech | 2022 | 36037004 | PubTator, text mining | PubMed |
| Genetics and clinical phenotype of Erdheim-Chester disease: A case report of constrictive pericarditis and a systematic review of the literature. | Front Cardiovasc Med | 2022 | 36035941 | PubTator, text mining | PubMed |
| The current state of the art and future trends in RAS-targeted cancer therapies. | Nat Rev Clin Oncol | 2022 | 36028717 | PubTator, text mining | PubMed |
| Cyclosporine A Modulates LSP1 Protein Levels in Human B Cells to Attenuate B Cell Migration at Low O2 Levels. | Life (Basel) | 2022 | 36013463 | PubTator, text mining | PubMed |
| Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. | Genes (Basel) | 2022 | 36011410 | PubTator, text mining | PubMed |
| Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations. | Biomedicines | 2022 | 36009519 | PubTator, text mining | PubMed |
| Mechanisms and prospects of circular RNAs and their interacting signaling pathways in colorectal cancer. | Front Oncol | 2022 | 35992800 | PubTator, text mining | PubMed |
| Protocol for stratification of triple-negative breast cancer patients using in silico signaling dynamics. | STAR Protoc | 2022 | 35990741 | PubTator, text mining | PubMed |
| Rosai-Dorfman-Destombes disease - histiocytic disorder with inflammatory manifestation. | Klin Onkol | 2022 | 35989082 | PubTator, text mining | PubMed |
| Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. | Cancer Cell Int | 2022 | 35986321 | PubTator, text mining | PubMed |
| Conquering oncogenic KRAS and its bypass mechanisms. | Theranostics | 2022 | 35966590 | PubTator, text mining | PubMed |
| Downregulation of HNRNPM inhibits cell proliferation and migration of hepatocellular carcinoma through MAPK/AKT signaling pathway. | Transl Cancer Res | 2022 | 35966311 | PubTator, text mining | PubMed |
| Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. | Front Oncol | 2022 | 35965494 | PubTator, text mining | PubMed |
| A miR-34a-guided, tRNAiMet-derived, piR_019752-like fragment (tRiMetF31) suppresses migration and angiogenesis of breast cancer cells via targeting PFKFB3. | Cell Death Discov | 2022 | 35961977 | PubTator, text mining | PubMed |
| The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. | Int J Mol Sci | 2022 | 35955671 | PubTator, text mining | PubMed |
| Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. | JCO Precis Oncol | 2022 | 35952322 | PubTator, text mining | PubMed |
| Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations. | Cureus | 2022 | 35949786 | PubTator, text mining | PubMed |
| Clinical staging and genetic profiling of Korean patients with primary lymphedema using targeted gene sequencing. | Sci Rep | 2022 | 35948757 | PubTator, text mining | PubMed |
| USP7 regulates the ERK1/2 signaling pathway through deubiquitinating Raf-1 in lung adenocarcinoma. | Cell Death Dis | 2022 | 35948545 | PubTator, text mining | PubMed |
| Heterogeneity in RAS mutations: One size does not fit all. | Sci Signal | 2022 | 35944067 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/papers?page=21